Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2018
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Familial Mediterranean fever
- Focus Proof of concept; Therapeutic Use
- 09 May 2018 Planned End Date changed from 30 Apr 2020 to 30 May 2020.
- 09 May 2018 Planned primary completion date changed from 30 Nov 2019 to 30 Dec 2019.
- 09 May 2018 Status changed from not yet recruiting to recruiting.